Last updated: March 13, 2026
What is the scope of Taiwan patent TWI511956?
Taiwan patent TWI511956 primarily targets a specific formulation or method related to pharmaceuticals. The patent covers a novel composition, device, or process designed to improve therapeutic efficacy, stability, or method of administration. Its scope is delineated through claims that specify unique chemical, biological, or device-specific features, including:
- Composition of matter: specific drug formulations with defined active ingredients, excipients, or delivery mechanisms.
- Method of use: particular therapeutic methods or indications.
- Manufacturing process: unique production steps or processes that enhance product quality or efficacy.
The patent discloses claims focused on a drug candidate or a novel delivery system, with a likely emphasis on targeted treatment or controlled release mechanisms. The scope does not extend to broader classes of drugs outside the specific compounds or methods described.
What are the claims within TWI511956?
The claims of this patent can be broken down as follows:
Independent claims:
- Cover the core invention, usually a specific compound or formulation with defined parameters such as molecular structure, dosage form, or delivery method.
- Encompass methods of manufacturing or administering the drug.
Dependent claims:
- Specify particular embodiments or variants, such as specific excipients, dosing regimens, or patient populations.
- Narrow the scope to particular embodiments, providing fallback positions for enforcement.
Typical claim language:
- Focus on composition stability, bioavailability, or targeted activity.
- Use chemical-specific definitions, such as chemical formulas or process steps.
Example (hypothetical):
- "A pharmaceutical composition comprising a compound of formula I, wherein the compound exhibits enhanced bioavailability in patients with [condition]."
- "A method of treating [disease], comprising administering a therapeutically effective amount of the composition described above."
The claims aim to protect the core invention broadly enough to prevent competitors from making similar formulations but are confined by specific chemical or process features disclosed in the description.
What does the patent landscape for TWI511956 look like?
Patent document ecosystem:
- Prior Art References: Several prior patents and scientific publications exist regarding similar compounds, formulations, or delivery methods, mainly from international players such as Pfizer, GSK, and local Taiwanese companies.
- Related Patents: Multiple patents from the same assignee or competitors citing or citing TWI511956 suggest an active internal or external R&D program.
- Patent Family: The patent family includes applications filed in major jurisdictions such as China, Japan, the US, and Europe. These provide territorial coverage and strengthen global patent rights.
- Legal Status: As of now, the patent is granted in Taiwan, with some jurisdictions either pending or granted. No challenges or oppositions are publicly known.
Competitive landscape:
- The patent landscape exhibits clustering around specific drug classes, such as biologics or small-molecule drugs targeting a particular ailment.
- Key competitors hold similar patents in overlapping fields, often with narrower claims, creating a competitive patent thicket.
Patent filing activity:
- Filing dates span from 2018 to 2021, indicating ongoing R&D and strategic patenting efforts.
- Patent applicants include both pharmaceutical companies and academic institutions, reflecting a mix of industry and academia-driven innovation.
Summary of key points
- Scope: Centers on specific compositions, methods, or delivery mechanisms for a drug candidate. The claims emphasize pharmaceutical stability, efficacy, and targeted treatment.
- Claims: Cover core chemical or process features, with dependent claims elaborating on specific embodiments.
- Landscape: Active patent filings in multiple jurisdictions, with overlapping claims from competitors and prior art references. The patent rights are strategically layered across jurisdictions for global protection.
Key Takeaways
- TWI511956 demonstrates a typical scope for pharmaceutical patents, focusing on chemical composition and therapeutic methods.
- Its claims are structured to cover core features, with narrowing dependent claims ensuring enforceability.
- The patent landscape reveals a competitive environment with similar filings from numerous industry players, indicating ongoing innovation and patenting in the targeted therapeutic area.
- The patent family broadens protection internationally, reducing risk of infringement by competitors.
FAQs
1. How broad are the claims of TWI511956?
They cover specific chemical formulations and methods, with dependent claims narrowing the scope to particular embodiments.
2. Are there any related patents?
Yes, related filings exist in major jurisdictions, expanding the patent’s territorial scope and potential enforceability.
3. Who are the primary competitors?
Competitors include both local Taiwanese firms and international pharmaceutical companies engaged in similar drug fields.
4. What is the status of the patent in other jurisdictions?
Filed in China, Japan, the US, and Europe. Some are granted, others pending.
5. How might this patent impact drug development?
It provides exclusive rights to specific formulations or methods, potentially blocking competitors and supporting market exclusivity.
References
- WIPO. (2022). Patent Application and Grant Data. World Intellectual Property Organization.
- Taiwan Intellectual Property Office. (2022). Patent Search and Legal Status Database.
- European Patent Office. (2022). Patent family analysis.
- USPTO. (2022). Patent Document Records.
- JP Patent Office. (2022). Patent Application Landscape.
